Galapagos NV (GLPGF)
USD 22.39
(-54.02%)
USD 22.39
(-54.02%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 239.72 Million EUR | -52.56% |
| 2022 | 505.28 Million EUR | 4.21% |
| 2021 | 484.84 Million EUR | 1.42% |
| 2020 | 478.05 Million EUR | -43.42% |
| 2019 | 844.98 Million EUR | 192.55% |
| 2018 | 288.83 Million EUR | 127.27% |
| 2017 | 127.08 Million EUR | -1.88% |
| 2016 | 129.51 Million EUR | 227.37% |
| 2015 | 39.56 Million EUR | -42.97% |
| 2014 | 69.36 Million EUR | -49.62% |
| 2013 | 137.69 Million EUR | 1.05% |
| 2012 | 136.26 Million EUR | 42.11% |
| 2011 | 95.88 Million EUR | -21.67% |
| 2010 | 122.41 Million EUR | 31.5% |
| 2009 | 93.08 Million EUR | 20.93% |
| 2008 | 76.97 Million EUR | 16.75% |
| 2007 | 65.93 Million EUR | 87.57% |
| 2006 | 35.15 Million EUR | 212.74% |
| 2005 | 11.24 Million EUR | 44.53% |
| 2004 | 7.77 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 77.87 Million EUR | 24.73% |
| 2024 Q1 | 62.43 Million EUR | 129.85% |
| 2023 Q3 | 120.02 Million EUR | -19.96% |
| 2023 FY | 239.7 Million EUR | -52.56% |
| 2023 Q1 | 178.86 Million EUR | 88.04% |
| 2023 Q2 | 149.95 Million EUR | -16.17% |
| 2023 Q4 | -209.12 Million EUR | -274.23% |
| 2022 Q2 | 137.6 Million EUR | 0.93% |
| 2022 Q1 | 136.34 Million EUR | -18.35% |
| 2022 FY | 505.28 Million EUR | 4.21% |
| 2022 Q4 | 95.12 Million EUR | -30.16% |
| 2022 Q3 | 136.2 Million EUR | -1.02% |
| 2021 FY | 484.84 Million EUR | 1.42% |
| 2021 Q2 | 139.77 Million EUR | 22.72% |
| 2021 Q4 | 166.98 Million EUR | 160.13% |
| 2021 Q3 | 64.19 Million EUR | -54.07% |
| 2021 Q1 | 113.89 Million EUR | -21.16% |
| 2020 Q2 | 103.6 Million EUR | 5.53% |
| 2020 Q4 | 144.46 Million EUR | 9.6% |
| 2020 FY | 478.05 Million EUR | -43.42% |
| 2020 Q1 | 98.17 Million EUR | -17.69% |
| 2020 Q3 | 131.81 Million EUR | 27.24% |
| 2019 Q2 | 58.73 Million EUR | 77.74% |
| 2019 Q1 | 33.04 Million EUR | -68.93% |
| 2019 FY | 844.98 Million EUR | 192.55% |
| 2019 Q4 | 119.26 Million EUR | -81.19% |
| 2019 Q3 | 633.93 Million EUR | 979.26% |
| 2018 Q2 | 49.67 Million EUR | 31.05% |
| 2018 Q4 | 106.37 Million EUR | 12.13% |
| 2018 FY | 288.83 Million EUR | 127.27% |
| 2018 Q3 | 94.87 Million EUR | 90.99% |
| 2018 Q1 | 37.9 Million EUR | -3.34% |
| 2017 Q2 | 26.93 Million EUR | -20.77% |
| 2017 Q1 | 33.99 Million EUR | -57.25% |
| 2017 FY | 127.08 Million EUR | -1.88% |
| 2017 Q3 | 26.94 Million EUR | 0.04% |
| 2017 Q4 | 39.21 Million EUR | 45.54% |
| 2016 Q2 | 28.67 Million EUR | 183.35% |
| 2016 Q1 | 10.12 Million EUR | 40.71% |
| 2016 Q3 | 11.21 Million EUR | -60.9% |
| 2016 FY | 129.51 Million EUR | 227.37% |
| 2016 Q4 | 79.5 Million EUR | 609.08% |
| 2015 FY | 39.56 Million EUR | -42.97% |
| 2015 Q4 | 7.19 Million EUR | 26.06% |
| 2015 Q3 | 5.7 Million EUR | -51.93% |
| 2015 Q2 | 11.86 Million EUR | -19.8% |
| 2015 Q1 | 14.79 Million EUR | -26.91% |
| 2014 FY | 69.36 Million EUR | -49.62% |
| 2014 Q4 | 20.24 Million EUR | 48.16% |
| 2014 Q3 | 13.66 Million EUR | -39.34% |
| 2014 Q1 | 22.52 Million EUR | -4.85% |
| 2014 Q2 | 22.52 Million EUR | 0.0% |
| 2013 FY | 137.69 Million EUR | 1.05% |
| 2013 Q1 | 24.61 Million EUR | 0.0% |
| 2013 Q2 | 24.61 Million EUR | 0.0% |
| 2013 Q4 | 23.67 Million EUR | 0.0% |
| 2013 Q3 | 23.67 Million EUR | -3.8% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 FY | 136.26 Million EUR | 42.11% |
| 2011 FY | 95.88 Million EUR | -21.67% |
| 2011 Q2 | - EUR | 0.0% |
| 2010 Q2 | - EUR | 0.0% |
| 2010 FY | 122.41 Million EUR | 31.5% |
| 2009 Q2 | - EUR | 0.0% |
| 2009 FY | 93.08 Million EUR | 20.93% |
| 2008 FY | 76.97 Million EUR | 16.75% |
| 2007 FY | 65.93 Million EUR | 87.57% |
| 2006 FY | 35.15 Million EUR | 212.74% |
| 2005 FY | 11.24 Million EUR | 44.53% |
| 2004 FY | 7.77 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Qrons Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | -94.971% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -36304.556% |
| Capstone Therapeutics Corp. | 48.35 Million USD | -395.769% |
| BioStem Technologies, Inc. | 16.68 Million USD | -1336.729% |
| CSL Limited | 14.69 Billion USD | 98.368% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -316475.986% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -1215.863% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -12308.075% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -101237.504% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -1419.838% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -1360344.924% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 21.47 Million USD | -1016.137% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -364621.276% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Mesoblast Limited | 5.9 Million USD | -3961.742% |
| Marizyme, Inc. | 645.81 Thousand USD | -37019.896% |
| Genus plc | 668.8 Million USD | 64.156% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | 2.28% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -242060.131% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -58345.747% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -312199.214% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -606519.768% |
| MultiCell Technologies, Inc. | 49.32 USD | -486058294.161% |
| ONE Bio Corp. | 52.29 Million USD | -358.397% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 49.72 Million USD | -382.138% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -490133.129% |
| Q BioMed Inc. | 284.35 Thousand USD | -84205.368% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | -709.96% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | -65.213% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -42883.629% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -342362.857% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -23996296.396% |
| Enzolytics Inc. | 52.79 Thousand USD | -453957.126% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -39294.273% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | 80.452% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -170835.954% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -38728.995% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 839.52 Million USD | 71.445% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -23927.037% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -101237.504% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.36 Million USD | -17410.884% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -50503.508% |
| SYBLEU INC | 11.69 Thousand USD | -2049523.803% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -2977.725% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -1843930.769% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -606274.26% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -7098.919% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -3496.759% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -22972.57% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -830.353% |
| CSL Limited | 14.8 Billion USD | 98.38% |
| Cellectis S.A. | 755 Thousand USD | -31651.523% |